论文部分内容阅读
本文用~(125)I标记导向药物测定其药时曲线和体内分布,提出初步数学模型,计算出其药代动力学参数,并与柔红霉素(DNR)在白血病患者的药代动力学参数进行比较,以评估导向药物在临床应用中的价值。与此同时建立了测定导向药物HI30-PAD-DNR中柔红霉素的水解产物柔红酮(daunomycinone,DNRO)非同位素测定导向药物血药浓度方法。为将来导向药物Ⅰ期和Ⅱ期临床
In this paper, the pharmacokinetics of ~ (125) I-labeled drug was measured and the pharmacokinetic parameters were calculated. The pharmacokinetics of daunorubicin (DNR) in patients with leukemia Parameters were compared to evaluate the value of the guide drug in clinical applications. At the same time, a non-isotopic determination of drug-induced plasma concentration of daunomycinone (DNRO), a hydrolysates of daunorubicin in HI30-PAD-DNR, was established. For the future oriented drugs Ⅰ and Ⅱ clinical